Epanova™ Free Fatty Acids for Symptomatic Remission Maintenance in Crohn's Disease

Crohn's disease is a long-term condition that causes inflammation in the digestive system, leading to symptoms like abdominal pain, diarrhea, and fatigue. Current treatments for maintaining remission in Crohn's disease are not sufficient, often leaving patients with a poor quality of life. This study focuses on a drug called Epanova™, a form of marine fish oil, which has shown potential in reducing inflammation in similar conditions. The goal of this research is to evaluate if Epanova™ can effectively maintain symptomatic remission in Crohn's disease patients who respond to steroid induction therapy. During this trial, participants who respond to steroid induction therapy will be given either Epanova™ or a placebo. Epanova™ is designed to be well-tolerated and to deliver a high concentration of marine fish oils. The study will assess the safety and tolerability of Epanova™, its ability to maintain quality of life, and its effectiveness in reducing disease activity. The study also considers factors like employment status and use of Crohn's disease-related medical visits to measure the impact of the treatment.